Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

A. Younes, LH. Sehn, P. Johnson, PL. Zinzani, X. Hong, J. Zhu, C. Patti, D. Belada, O. Samoilova, C. Suh, S. Leppä, S. Rai, M. Turgut, W. Jurczak, MC. Cheung, R. Gurion, SP. Yeh, A. Lopez-Hernandez, U. Dührsen, C. Thieblemont, CS. Chiattone, S....

. 2019 ; 37 (15) : 1285-1295. [pub] 20190322

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023941

Grantová podpora
P30 CA008748 NCI NIH HHS - United States

PURPOSE: Ibrutinib has shown activity in non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in untreated non-germinal center B-cell DLBCL. PATIENTS AND METHODS: Patients were randomly assigned at a one-to-one ratio to ibrutinib (560 mg per day orally) plus R-CHOP or placebo plus R-CHOP. The primary end point was event-free survival (EFS) in the intent-to-treat (ITT) population and the activated B-cell (ABC) DLBCL subgroup. Secondary end points included progression-free survival (PFS), overall survival (OS), and safety. RESULTS: A total of 838 patients were randomly assigned to ibrutinib plus R-CHOP (n = 419) or placebo plus R-CHOP (n = 419). Median age was 62.0 years; 75.9% of evaluable patients had ABC subtype disease, and baseline characteristics were balanced. Ibrutinib plus R-CHOP did not improve EFS in the ITT (hazard ratio [HR], 0.934) or ABC (HR, 0.949) population. A preplanned analysis showed a significant interaction between treatment and age. In patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS (HR, 0.579), PFS (HR, 0.556), and OS (HR, 0.330) and slightly increased serious adverse events (35.7% v 28.6%), but the proportion of patients receiving at least six cycles of R-CHOP was similar between treatment arms (92.9% v 93.0%). In patients age 60 years or older, ibrutinib plus R-CHOP worsened EFS, PFS, and OS, increased serious adverse events (63.4% v 38.2%), and decreased the proportion of patients receiving at least six cycles of R-CHOP (73.7% v 88.8%). CONCLUSION: The study did not meet its primary end point in the ITT or ABC population. However, in patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS, PFS, and OS with manageable safety. In patients age 60 years or older, ibrutinib plus R-CHOP was associated with increased toxicity, leading to compromised R-CHOP administration and worse outcomes. Further investigation is warranted.

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello Palermo Italy

BC Cancer Agency Vancouver British Columbia Canada

Charles University Hradec Králové Czech Republic 9 University Hospital Hradec Králové Hradec Králové Czech Republic

China Medical University Hospital Taichung Republic of China

Fudan University Shanghai People's Republic of China

Helsinki University Hospital Helsinki Finland 13 University of Helsinki Helsinki Finland

Hôpital Saint Louis Paris France 24 Diderot University Sorbonne Paris Cité Paris France

Jagiellonian University Krakow Poland

Janssen Research and Development Leiden the Netherlands

Janssen Research and Development Raritan NJ

Janssen Research and Development San Diego CA

Janssen Research and Development Spring House PA

Kindai University Osakasayama Japan

Memorial Sloan Kettering Cancer Center New York NY

National Cancer Institute National Institutes of Health Bethesda MD

Ondokuz Mayis University Samsun Turkey

Peking University Cancer Hospital Beijing People's Republic of China

Rabin Medical Center Petah Tikva Israel 19 Tel Aviv University Tel Aviv Israel

Regional Clinical Hospital Nizhny Novgorod Russian Federation

Santa Casa Medical School São Paulo Brazil

Seràgnoli University of Bologna Bologna Italy

Sunnybrook Odette Cancer Centre Toronto Ontario Canada

University Hospital Essen Essen Germany

University Hospital Vall d'Hebron Barcelona Spain

University of Southampton Southampton United Kingdom

University of Ulsan Seoul Republic of Korea

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023941
003      
CZ-PrNML
005      
20240313110014.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.18.02403 $2 doi
035    __
$a (PubMed)30901302
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Younes, Anas $u Memorial Sloan Kettering Cancer Center, New York, NY.
245    10
$a Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma / $c A. Younes, LH. Sehn, P. Johnson, PL. Zinzani, X. Hong, J. Zhu, C. Patti, D. Belada, O. Samoilova, C. Suh, S. Leppä, S. Rai, M. Turgut, W. Jurczak, MC. Cheung, R. Gurion, SP. Yeh, A. Lopez-Hernandez, U. Dührsen, C. Thieblemont, CS. Chiattone, S. Balasubramanian, J. Carey, G. Liu, SM. Shreeve, S. Sun, SH. Zhuang, J. Vermeulen, LM. Staudt, W. Wilson, PHOENIX investigators,
520    9_
$a PURPOSE: Ibrutinib has shown activity in non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in untreated non-germinal center B-cell DLBCL. PATIENTS AND METHODS: Patients were randomly assigned at a one-to-one ratio to ibrutinib (560 mg per day orally) plus R-CHOP or placebo plus R-CHOP. The primary end point was event-free survival (EFS) in the intent-to-treat (ITT) population and the activated B-cell (ABC) DLBCL subgroup. Secondary end points included progression-free survival (PFS), overall survival (OS), and safety. RESULTS: A total of 838 patients were randomly assigned to ibrutinib plus R-CHOP (n = 419) or placebo plus R-CHOP (n = 419). Median age was 62.0 years; 75.9% of evaluable patients had ABC subtype disease, and baseline characteristics were balanced. Ibrutinib plus R-CHOP did not improve EFS in the ITT (hazard ratio [HR], 0.934) or ABC (HR, 0.949) population. A preplanned analysis showed a significant interaction between treatment and age. In patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS (HR, 0.579), PFS (HR, 0.556), and OS (HR, 0.330) and slightly increased serious adverse events (35.7% v 28.6%), but the proportion of patients receiving at least six cycles of R-CHOP was similar between treatment arms (92.9% v 93.0%). In patients age 60 years or older, ibrutinib plus R-CHOP worsened EFS, PFS, and OS, increased serious adverse events (63.4% v 38.2%), and decreased the proportion of patients receiving at least six cycles of R-CHOP (73.7% v 88.8%). CONCLUSION: The study did not meet its primary end point in the ITT or ABC population. However, in patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS, PFS, and OS with manageable safety. In patients age 60 years or older, ibrutinib plus R-CHOP was associated with increased toxicity, leading to compromised R-CHOP administration and worse outcomes. Further investigation is warranted.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a cyklofosfamid $x aplikace a dávkování $x škodlivé účinky $7 D003520
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a doxorubicin $x aplikace a dávkování $x škodlivé účinky $7 D004317
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a difúzní velkobuněčný B-lymfom $x farmakoterapie $7 D016403
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a placebo $7 D010919
650    _2
$a prednison $x aplikace a dávkování $x škodlivé účinky $7 D011241
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a pyrazoly $x aplikace a dávkování $x škodlivé účinky $7 D011720
650    _2
$a pyrimidiny $x aplikace a dávkování $x škodlivé účinky $7 D011743
650    _2
$a rituximab $x aplikace a dávkování $x škodlivé účinky $7 D000069283
650    _2
$a míra přežití $7 D015996
650    _2
$a vinkristin $x aplikace a dávkování $x škodlivé účinky $7 D014750
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sehn, Laurie H $u BC Cancer Agency, Vancouver, British Columbia, Canada.
700    1_
$a Johnson, Peter $u University of Southampton, Southampton, United Kingdom.
700    1_
$a Zinzani, Pier Luigi, $d 1959- $u "Seràgnoli" University of Bologna, Bologna, Italy. $7 xx0314852
700    1_
$a Hong, Xiaonan $u Fudan University, Shanghai, People's Republic of China.
700    1_
$a Zhu, Jun $u Peking University Cancer Hospital, Beijing, People's Republic of China.
700    1_
$a Patti, Caterina $u Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.
700    1_
$a Belada, David $u Charles University, Hradec Králové, Czech Republic. 9 University Hospital Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Samoilova, Olga $u Regional Clinical Hospital, Nizhny Novgorod, Russian Federation.
700    1_
$a Suh, Cheolwon $u University of Ulsan, Seoul, Republic of Korea.
700    1_
$a Leppä, Sirpa $u Helsinki University Hospital, Helsinki, Finland. 13 University of Helsinki, Helsinki, Finland.
700    1_
$a Rai, Shinya $u Kindai University, Osakasayama, Japan.
700    1_
$a Turgut, Mehmet $u Ondokuz Mayis University, Samsun, Turkey.
700    1_
$a Jurczak, Wojciech $u Jagiellonian University, Krakow, Poland.
700    1_
$a Cheung, Matthew C $u Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.
700    1_
$a Gurion, Ronit $u Rabin Medical Center, Petah Tikva, Israel. 19 Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Yeh, Su-Peng $u China Medical University Hospital, Taichung, Republic of China.
700    1_
$a Lopez-Hernandez, Andres $u University Hospital Vall d'Hebron, Barcelona, Spain.
700    1_
$a Dührsen, Ulrich $u University Hospital Essen, Essen, Germany.
700    1_
$a Thieblemont, Catherine $u Hôpital Saint-Louis, Paris, France. 24 Diderot University, Sorbonne Paris-Cité, Paris, France.
700    1_
$a Chiattone, Carlos Sergio $u Santa Casa Medical School, São Paulo, Brazil.
700    1_
$a Balasubramanian, Sriram $u Janssen Research and Development, San Diego, CA.
700    1_
$a Carey, Jodi $u Janssen Research and Development, Spring House, PA.
700    1_
$a Liu, Grace $u Janssen Research and Development, Raritan, NJ.
700    1_
$a Shreeve, S Martin $u Janssen Research and Development, San Diego, CA.
700    1_
$a Sun, Steven $u Janssen Research and Development, Raritan, NJ.
700    1_
$a Zhuang, Sen Hong $u Janssen Research and Development, Raritan, NJ.
700    1_
$a Vermeulen, Jessica $u Janssen Research and Development, Leiden, the Netherlands.
700    1_
$a Staudt, Louis M $u National Cancer Institute, National Institutes of Health, Bethesda, MD.
700    1_
$a Wilson, Wyndham $u National Cancer Institute, National Institutes of Health, Bethesda, MD.
710    2_
$a PHOENIX investigators
773    0_
$w MED00002596 $t Journal of clinical oncology $x 1527-7755 $g Roč. 37, č. 15 (2019), s. 1285-1295
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30901302 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20240313110009 $b ABA008
999    __
$a ok $b bmc $g 1596260 $s 1114617
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 37 $c 15 $d 1285-1295 $e 20190322 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
GRA    __
$a P30 CA008748 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace